# Tesamorelin FAQ: Fat Loss, Liver Fat, Safety, and FDA Status

> Tesamorelin questions answered from the literature: belly fat, liver fat, IGF-1, blood sugar, half-life, who should avoid it, FDA status, and whether it works outside HIV — each answer cited.

Direct, cited answers to the questions readers most often ask about tesamorelin — fat loss, liver fat, safety, and regulatory status.

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone, GHRH(1-44), with an N-terminal trans-3-hexenoyl group that resists DPP-IV cleavage [4]. It stimulates the body's own pulsatile growth hormone and raises IGF-1 [1]. It was FDA-approved in 2010 only for HIV-associated lipodystrophy [5].

## What does tesamorelin do?

It binds the pituitary GHRH receptor to stimulate endogenous growth hormone, which raises IGF-1 and promotes fat breakdown preferentially in visceral depots [4]. In its approved HIV-lipodystrophy use, the pivotal trial reduced visceral adipose tissue by 15.2% versus a 5.0% increase on placebo [1].

## Will tesamorelin help with belly fat?

In HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% in the pivotal trial versus a 5.0% increase on placebo [1]. This research is in HIV-associated lipodystrophy; no large general-population fat-loss trial has been completed [5].

## How quickly was fat loss seen in trials?

The pivotal trials measured visceral-fat reduction at 26 weeks, with the effect sustained to 52 weeks (-18% versus baseline) [2]. A 2024 trial in the integrase-inhibitor era measured reductions over 12 months [10].

## Does tesamorelin reduce abdominal fat?

In the 52-week HIV program, visceral fat was reduced and sustained at -18% versus baseline [2], and a 2026 meta-analysis of five trials reported a pooled reduction of -27.71 cm2 (95% CI -38.37 to -17.06) [12]. The effect is selective for visceral, not subcutaneous, fat, which was preserved in trials [1].

## How much visceral fat was lost in trials?

In the pivotal HIV trial, visceral adipose tissue fell 15.2% over 26 weeks (sustained at -18% to 52 weeks) [1][2]; the 2026 meta-analysis reported a pooled reduction of -27.71 cm2 [12]. These figures are from HIV-associated lipodystrophy trials, not general weight loss.

## What happens when tesamorelin is stopped?

Visceral fat reaccumulates upon discontinuation; in the 52-week program the benefit reversed when treatment stopped [2]. The effect is contingent on continued dosing — it is not a one-time correction.

## Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?

In a 12-month Lancet HIV trial (n=61), tesamorelin 2 mg/day reduced hepatic fat fraction by 37% relative to placebo (P=0.016), and 35% versus 4% of patients reached a fraction below 5% (P=0.0069); the authors noted further study of liver histology is needed [6]. It is studied in HIV-associated NAFLD, not approved for general NAFLD.

## How does tesamorelin affect the liver in NAFLD?

Liver-tissue transcriptomics after 12 months of tesamorelin in HIV patients with NAFLD showed upregulated oxidative-phosphorylation gene sets and downregulated inflammatory and tissue-remodeling pathways — a mechanistic correlate for the observed reduction in hepatic fat [8].

## Can tesamorelin reduce liver fat?

In a 6-month JAMA trial (n=50), the net reduction in hepatic lipid-to-water percentage was -2.9% (P=0.003) [3]; a 2026 meta-analysis of five trials reported a pooled hepatic-fat-fraction reduction of -4.28% [12]. All such data are in HIV-associated fatty liver disease.

## How does tesamorelin work?

Tesamorelin activates the Gs-coupled GHRH receptor on pituitary somatotrophs (a cAMP/PKA cascade), stimulating synthesis and pulsatile secretion of growth hormone; the resulting growth hormone drives hepatic IGF-1 and visceral-fat breakdown [4]. In 13 healthy men it raised IGF-1 by 181 ug/L [4].

## Is tesamorelin a growth hormone?

No. Tesamorelin is a GHRH analogue: it stimulates the pituitary to release the body's own growth hormone rather than supplying exogenous growth hormone. In healthy men it raised mean overnight growth hormone by 0.5 ug/L and IGF-1 by 181 ug/L [4].

## How does tesamorelin stimulate growth hormone release?

It binds the GHRH receptor on pituitary somatotrophs (a Gs-coupled receptor), raising intracellular cAMP and activating PKA to drive growth-hormone gene transcription and pulsatile secretion [4]. The trans-3-hexenoic acid modification on the N-terminus resists DPP-IV, extending activity relative to native GHRH [4].

## Does tesamorelin raise IGF-1 levels?

Yes. By stimulating endogenous growth hormone, tesamorelin raises IGF-1: +81.0% in the pivotal HIV trial [1] and +181 ug/L in healthy men over two weeks [4]. The rise in IGF-1 underlies both the lipolytic effect and the growth-factor safety considerations [5].

## Does tesamorelin affect blood sugar?

In 13 healthy men, neither fasting glucose (P=0.93) nor insulin-stimulated glucose uptake (P=0.61) changed significantly over two weeks [4]. The 52-week HIV program found glucose changes that were not clinically significant [2]. Monitoring is still warranted in people with prediabetes or dysglycemia.

## Does tesamorelin cause water retention?

Fluid retention is a recognized growth-hormone-class effect noted with growth-hormone-axis stimulation. Because tesamorelin raises endogenous growth hormone and IGF-1, growth-hormone-class effects are described in its safety profile; effects were generally mild in trials [2].

## What are the side effects of tesamorelin?

Reported effects relate to growth-hormone-axis stimulation and raised IGF-1; the NIH LiverTox monograph assigns a likelihood score of E (unlikely cause of liver injury) with no attributable cases [5]. Trials reported injection-site reactions and modest glucose perturbation [2]; active malignancy and pregnancy are labeled contraindications [5].

## Who should not take tesamorelin?

The FDA prescribing label contraindicates use in active malignancy (treatment must be complete and the malignancy inactive), known hypersensitivity to tesamorelin or excipients, and pregnancy (animal organogenesis studies showed hydrocephaly in offspring) [5]. It is also prohibited in sport under the WADA list (category S2).

## Does tesamorelin work for fat loss in non-HIV users?

Pivotal efficacy trials were conducted in HIV-positive adults on antiretroviral therapy [1][2]. Generalizability to non-HIV populations is mechanistically plausible but not established by large trials; non-HIV human data are limited to a mechanistic study in healthy men [4] and a cognition trial.

## What is the half-life of tesamorelin?

Plasma exposure is short: population PK modeling reported apparent clearance of about 1,060 L/h [15], and secondary sources (the FDA label, Mayo Clinic) describe a terminal half-life on the order of 26-38 minutes. Despite rapid clearance, downstream IGF-1 elevation persists across the dosing interval [4].

## How long does tesamorelin stay in your system?

The peptide itself clears rapidly (apparent clearance about 1,060 L/h; terminal half-life roughly 26-38 minutes per secondary sources) [15], but its downstream effect on IGF-1 is sustained across the day, which is why a once-daily regimen was studied [4].

## Is tesamorelin FDA approved?

Yes, but narrowly: tesamorelin was approved in the United States in 2010 (NDA 022505) only to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [5]. Every other use — general or cosmetic fat loss, anti-aging, performance — is off-label and not FDA-approved.

## Who should not take tesamorelin or who should avoid it?

Per the FDA label, tesamorelin is contraindicated in active malignancy, known hypersensitivity to the drug or excipients, and pregnancy [5]. Caution and glucose monitoring apply in dysglycemia [2], and it is prohibited in sport under WADA category S2.

---

A clear-light reading of the tesamorelin record — every trial figure logged at the snow-line where the approved HIV-lipodystrophy use ends and the off-label questions begin; a luminous reference plate, not a clinic, a pharmacy, or a prescription.